Clinical Drug Investigation

, Volume 33, Issue 7, pp 477–488

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Inhaled Doses of Umeclidinium in Healthy Subjects: Two Randomized Studies

  • Anthony Cahn
  • Ruth Tal-Singer
  • Isabelle J. Pouliquen
  • Rashmi Mehta
  • Andrew Preece
  • Kelly Hardes
  • Glenn Crater
  • Amanda Deans
Original Research Article

Abstract

Background

Chronic obstructive pulmonary disease (COPD) has a significant negative impact on quality of life and increases the risk of premature death. Umeclidinium is a long-acting muscarinic receptor antagonist in development for the treatment of COPD with the aim to broaden treatment options for clinicians and patients by providing improved symptom control.

Objective

To characterize the safety, tolerability, pharmacokinetics and pharmacodynamics of single and repeat inhaled doses of umeclidinium in healthy subjects.

Study Design

Two randomized, placebo-controlled, ascending-dose studies were conducted in healthy ipratropium bromide-responsive subjects. In the single-dose study, subjects (n = 20) received umeclidinium (10–350 μg), tiotropium bromide 18 μg and placebo in a crossover dosing schedule. In this study, lung function was assessed for 24 h by measuring specific airways conductance (sGaw) and forced expiratory volume in 1 s (FEV1). In the repeat-dose study, subjects (n = 36) received umeclidinium (250–1,000 μg) and placebo for 14 days in a parallel-group schedule.

Results

Adverse events (AEs) were reported in five subjects (single-dose study) and 23 subjects (repeat-dose study); none were serious. In both studies, no abnormalities in 12-lead electrocardiogram parameters, 24-h Holter monitoring or lead II monitoring were reported as AEs. Umeclidinium was rapidly absorbed following single-dose administration [time to reach the maximum plasma concentration (tmax) 5–15 min] and repeat-dose administration (tmax 5–7 min). Following repeat dosing, the geometric mean plasma elimination half-life was approximately 27 h and statistically significant accumulation was observed for the area under the plasma concentration–time curve, maximum plasma concentration and cumulative amount of unchanged drug excreted into the urine at 24 h (range 1.5- to 4.5-fold). Umeclidinium at doses of 100 μg and above, and tiotropium bromide demonstrated statistically significant bronchodilatory effects relative to placebo at 12 h post-dosing, which lasted up to 24 h for umeclidinium 350 μg and for tiotropium bromide. Relative to placebo, these increases in sGaw were 24–34 % at 12 h post-dose and 13 % at 24 h post-dose. Increases in FEV1 achieved statistical significance at 12 and 24 h for umeclidinium 100 μg and 350 μg compared with placebo.

Conclusion

Umeclidinium was well tolerated and demonstrated bronchodilatory effects in healthy subjects for up to 24 h. These bronchodilatory effects can be potentially clinically important in patients with airway obstruction such as COPD. The data obtained have informed dose selection for subsequent trials in subjects with COPD.

Supplementary material

40261_2013_88_MOESM1_ESM.docx (175 kb)
Supplementary material (DOCX 174 kb)

References

  1. 1.
    Karner C, Cates CJ. Combination inhaled steroid and long-acting beta(2)-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2011;(3):CD008532.Google Scholar
  2. 2.
    Russell R, Anzueto A, Weisman I. Optimizing management of chronic obstructive pulmonary disease in the upcoming decade. Int J Chron Obstruct Pulmon Dis. 2011;6:47–61.PubMedGoogle Scholar
  3. 3.
    Shavelle RM, Paculdo DR, Kush SJ, et al. Life expectancy and years of life lost in chronic obstructive pulmonary disease: findings from the NHANES III Follow-up Study. Int J Chron Obstruct Pulmon Dis. 2009;4:137–48.PubMedCrossRefGoogle Scholar
  4. 4.
    From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2011. http://www.goldcopd.org/. Accessed 17 Jan 2012.
  5. 5.
    Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000;320:1297–303.PubMedCrossRefGoogle Scholar
  6. 6.
    Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med. 2008;178:332–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Eglen RM, Hegde SS, Watson N. Muscarinic receptor subtypes and smooth muscle function. Pharmacol Rev. 1996;48:531–65.PubMedGoogle Scholar
  8. 8.
    Lainé DI, Luttmann MA, Foley JJ, et al. The pre-clinical pharmacology of the inhaled muscarinic antagonist GSK573719 predicts once-daily clinical dosing. Eur Respir J. 2011;38(Suppl. 55):3450.Google Scholar
  9. 9.
    World Medical Association. Declaration of Helsinki – ethical principles for medical research involving human subjects. Version October 1996. http://www.wma.net/en/30publications/10policies/b3/. Accessed 12 Dec 2011.
  10. 10.
    Algate C, et al. Umeclidinium (GSK573719) investigator’s brochure. Research Triangle Park: GlaxoSmithKline; 2012 (Data on file).Google Scholar
  11. 11.
    Singh D, Tal-Singer R, Faiferman I, et al. Plethysmography and impulse oscillometry assessment of tiotropium and ipratropium bromide; a randomised, double blind, placebo controlled, crossover study in healthy subjects. Brit J Clin Pharm. 2006;61:398–404.PubMedCrossRefGoogle Scholar
  12. 12.
    Caillaud D, Le Merre C, Martinat Y, et al. A dose-ranging study of tiotropium delivered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients. Int J Chron Obstruct Pulmon Dis. 2007;2:559–65.PubMedGoogle Scholar
  13. 13.
    Kesten S, Jara M, Wentworth C, et al. Pooled clinical trial analysis of tiotropium safety. Chest. 2006;130:1695–703.PubMedCrossRefGoogle Scholar
  14. 14.
    Salpeter SR. Do inhaled anticholinergics increase or decrease the risk of major cardiovascular events? A synthesis of the available evidence. Drugs. 2009;69:2025–33.PubMedCrossRefGoogle Scholar
  15. 15.
    Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008;300:1439–50.PubMedCrossRefGoogle Scholar
  16. 16.
    Agh T, Inotai A, Meszaros A. Factors associated with medication adherence in patients with chronic obstructive pulmonary disease. Respiration. 2011;82:328–34.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  • Anthony Cahn
    • 1
  • Ruth Tal-Singer
    • 2
  • Isabelle J. Pouliquen
    • 3
  • Rashmi Mehta
    • 4
  • Andrew Preece
    • 3
  • Kelly Hardes
    • 3
  • Glenn Crater
    • 5
  • Amanda Deans
    • 3
  1. 1.Medicines Discovery and DevelopmentGlaxoSmithKlineStevenageUK
  2. 2.GlaxoSmithKlineKing of PrussiaUSA
  3. 3.GlaxoSmithKlineUxbridgeUK
  4. 4.GlaxoSmithKlineResearch Triangle ParkUSA
  5. 5.GlaxoSmithKlineMississaugaCanada

Personalised recommendations